On October 20, the STXBP1 Foundation brought the STXBP1 patient community together for a first ever Externally-Led Patient-Focused Drug Development Meeting (ELPFDD), to inform the FDA and other stakeholders about the patient perspective of living with STXBP1-related disorders.
This information can help the FDA to make informed decisions on approvals of potential medicines for STXBP1-related disorders, and pharmaceutical companies to design clinical trials that are meaningful for patients.
The virtual meeting with the FDA was on October 20 from 10am-3pm ET.
We appreciated the testimonials from our community and always love to hear your voices!
